Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Kymera Therapeutics Inc (KYMR)

254 + Investors. Track Smart Money conviction in KYMR. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +4
Streak
2Q ▲
Buyers last Q
55%

Smart Money Signals — KYMR

Based on 256 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added KYMR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
256 hedge funds hold KYMR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +47% more funds vs a year ago

fund count last 6Q
+82 new funds entered over the past year (+47% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 55% buying

140 buying114 selling
Last quarter: 140 funds bought or added vs 114 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-23 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 64 → 37 → 68 → 45. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
📌

Mixed — 39% long-term, 32% new

■ 39% conviction (2yr+) ■ 29% medium ■ 32% new
Of the 256 current holders: 99 (39%) held >2 years, 75 held 1–2 years, and 82 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
📈

Growing discovery — still being found

28 → 64 → 37 → 68 → 45 new funds/Q
New funds entering each quarter: 64 → 37 → 68 → 45. A growing number of institutions are discovering KYMR each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 48% veterans vs 39% newcomers

■ 48% veterans ■ 13% 1-2yr ■ 39% new
Entry-cohort mix of 261 holders: 125 (48%) are 2+ year veterans, 35 entered 1–2 years ago, and 101 (39%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 41% AUM from top-100 funds

41% from top-100 AUM funds
52 of 254 holders are among the 100 largest funds by AUM, controlling 41% of total institutional value in KYMR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.4
out of 10
Moderate Exit Risk
Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — KYMR

In 2026 Q1, 140 hedge funds were net buyers of KYMR (45 opened a new position, 95 added to an existing one), while 114 reduced or exited (73 trimmed, 41 sold completely) — a 55% buyer ratio, indicating a slight buying edge. Net buying has persisted for two consecutive quarters, a positive momentum signal. 41% of total institutional value in KYMR is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +4 funds (more new holders than closures). Total institutional holders: 256.

Hedge Fund Ownership: KYMR

How many hedge funds hold KYMR — quarterly history vs. share price
Quarterly hedge fund ownership of KYMR vs. share price

Market Analysis: KYMR

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: KYMR

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Kymera Therapeutics Inc (KYMR) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much KYMR has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 46d ago
KYMR
+2.4%
XLV
+5.5%

KYMR outperformed XLV by -3.1% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 1d ago
KYMR
+0.0%
XLV
+0.0%

Since the filing became public, KYMR outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

25 top-rated funds 8 high-conviction
Consensus
6.1
/ 10
breadth
×
Elite
3.8
/ 10
conviction
Hedge Fund Positioning: KYMR
2026 Q2 Stats Unlock in 4 days 254 + Investors

Track Smart Money conviction in KYMR. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 254 251 1.2%
13F Shares 97M 90M 7.98%
Total Value $7.07B $6.49B 8.91%
New Positions 44 67 -23
Increased Positions 92 98 -6
Closed Positions 41 23 +18
Reduced Positions 72 64 +8
Total Calls 3 5 -40.0%
Total Puts 4 5 -20.0%
PUT/CALL Ratio 1.33 1.0 Bearish

Statistics: KYMR

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

254 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in KYMR. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 KYMR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Atlas Venture Life Science Advisors, LLC 37.05% 2,847,541 $326.5M
2 Merck & Co., Inc. 16.82% 772,165 $88.5M
3 Bvf Inc/Il 11.35% 3,872,052 $444.0M
4 Avoro Capital Advisors LLC 7.70% 7,474,747 $857.1M
5 Siren, L.L.C. 6.81% 2,935,830 $336.7M
6 AJU IB Investment Co., Ltd. 5.36% 19,648 $1.6M
7 Baker BROS. Advisors LP 4.97% 8,657,242 $992.7M
8 Boxer Capital Management, LLC 3.71% 429,100 $49.2M
9 Octagon Capital Advisors LP 3.20% 310,000 $35.5M
10 Eagle Health Investments LP 3.16% 166,148 $19.1M
11 Boone Capital Management LLC 3.04% 113,173 $13.0M
12 Nan Fung Group Holdings Ltd 2.69% 30,875 $3.5M
13 Foresite Capital Management VI LLC 2.61% 146,332 $16.8M
14 Rock Springs Capital Management LP 2.54% 453,156 $52.0M
15 Yiheng Capital Management, L.P. 2.50% 63,440 $7.3M
16 Diadema Partners LP 2.17% 149,700 $17.2M
17 Deer Management Co. LLC 1.78% 125,895 $14.4M
18 Commodore Capital LP 1.71% 250,000 $28.7M
19 Braidwell LP 1.60% 378,163 $43.4M
20 Nextech Invest Ltd. 1.52% 278,896 $32.0M
21 First Turn Management, LLC 1.26% 102,533 $11.8M
22 Scientech Research LLC 1.20% 12,943 $1.5M
23 Patient Square Capital LP 0.84% 47,500 $5.4M
24 Frontier Capital Management Co LLC 0.79% 740,866 $85.0M
25 Atika Capital Management LLC 0.78% 104,000 $11.9M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Kymera Therapeutics Inc (KYMR)

What does the Smart Money Trend signal show for KYMR?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added KYMR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for KYMR?

Slight buying edge — 55% buying: Last quarter: 140 funds bought or added vs 114 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for KYMR holders?

Elite ownership — 41% AUM from top-100 funds: 52 of 254 holders are among the 100 largest funds by AUM, controlling 41% of total institutional value in KYMR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held KYMR?

Mixed — 39% long-term, 32% new: Of the 256 current holders: 99 (39%) held >2 years, 75 held 1–2 years, and 82 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Kymera Therapeutics Inc (KYMR) following the 2026 Q2 hedge fund 13F filings?

As of today, KYMR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), KYMR has gained +2.4% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →